24,666 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by BML Capital Management LLC

BML Capital Management LLC purchased a new position in shares of Neurogene Inc. (NASDAQ:NGNE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,666 shares of the company’s stock, valued at approximately $478,000. Neurogene accounts for approximately 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 27th largest holding. BML Capital Management LLC owned approximately 1.05% of Neurogene at the end of the most recent quarter.

Neurogene Stock Down 3.0 %

Neurogene stock traded down $0.94 during mid-day trading on Wednesday, reaching $30.23. 52,572 shares of the company traded hands, compared to its average volume of 127,539. Neurogene Inc. has a fifty-two week low of $12.20 and a fifty-two week high of $53.00. The firm has a market capitalization of $388.46 million, a P/E ratio of -2.43 and a beta of 1.26. The company has a fifty day moving average price of $37.82.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. TD Cowen assumed coverage on shares of Neurogene in a report on Thursday, January 4th. They issued an “outperform” rating for the company. HC Wainwright boosted their price objective on shares of Neurogene from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. William Blair began coverage on shares of Neurogene in a research note on Thursday, March 21st. They set an “outperform” rating and a $61.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Neurogene in a research note on Friday, January 5th. They set a “buy” rating and a $31.00 price objective for the company.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.